• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

A Prescription for Election Fever

Now is the time to pop the pharmaceutical pill and buy.
By JOHN REESE
Oct 18, 2012 | 10:58 AM EDT
Stocks quotes in this article: GSK, NVS, PRGO

If the elections are giving you a tummy ache, heartburn or other malady, perhaps you need some pharmaceuticals. I am referring to pharmaceutical stocks, several of which are good investment opportunities at the moment.

The way I choose stocks is by relying on strategies I created by computer modeling the strategies of some of Wall Street's greatest investors. These are investors who have written books about how they invest or have had biographers write about their strategies. These strategies are essentially how hugely successful strategists work the market and two of these strategies think now is the time to pop the pharmaceutical pill and buy.

The strategy I base on the writing of James P. O'Shaughnessy is very much in favor of GlaxoSmithKline (GSK). One of the world's largest pharmaceutical companies, this British-based behemoth produces drugs, vaccines and consumer healthcare products and operates globally. The O'Shaughnessy strategy likes the company's large market cap ($114 billion), strong positive cash flow per share ($4.75), large number of shares outstanding (2.5 billion) and huge trailing 12-month sales ($44 billion). The strategy then selects among all the companies that have passed these four hurdles and chooses the top 50 based on their dividend yield. Glaxo's yield of 4.89% places it in this group.

Another member of Big Pharma is Novartis (NVS), headquartered in Switzerland. It develops, manufactures and markets a variety of healthcare products, including brandname pharmaceuticals, generics, eye care products, vaccines and consumer health products. Like Glaxo, Novartis gets the nod from my O'Shaughnessy-based strategy. In Novartis' favor, market cap of $170 billion, cash flow per share of $5.31, 2.4 billion shares outstanding and trailing 12-months sales of $58 billion. With a dividend yield of 3.93%, it earns a spot among the O'Shaughnessy top 50.

Glaxo and Novartis are among pharma's elite, but this next company is likely one you are not familiar with, even though Morningstar reports it holds a 70% share in its market. The company is Perrigo (PRGO), headquartered in Michigan. It calls itself "the world's largest manufacturer of OTC pharmaceutical products for the store brand market." If you go to a discount store, supermarket, drug store or other retailer and you see a name brand item on the shelf and next to it an equivalent product with the retailer's name, there's a good chance Perrigo made that store brand product. It also makes generic prescription drugs, nutritional products and dietary supplements, among other products. Morningstar says Wal-Mart (WMT) accounts for about 20% of the company's revenue.

I have a strategy based on the writings of Peter Lynch and it likes Perrigo. The most important variable used by this strategy is the P/E/G ratio, which is price-to-earnings relative to growth and is a means of gauging how much the investor is paying for growth. A P/E/G of 1.0 or less is acceptable and Perrigo comes in well below this ceiling with a P/E/G of 0.77, based on the average of the three-, four- and five-year historical EPS growth rates. In addition, the company is going a fine job managing its inventories.

These are solid, well-positioned companies with enviable track records. However you feel this election season, these drug companies have the power to make you feel all warm and fuzzy about your investments.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, John Reese and his clients were long Glaxo and Novartis.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jul 3, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • 07:59 PM EDT PAUL PRICE

    Very Good Quarterly Numbers From Bassett Furniture (BSET)

    Bassett Furniture blew right through analysts es...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login